Attention Deficit Hyperactivity Disorder Market (By Drug Type: Stimulants, Non-stimulants; By Demographics: Children, Adults; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Attention Deficit Hyperactivity Disorder Market 

5.1. COVID-19 Landscape: Attention Deficit Hyperactivity Disorder Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Attention Deficit Hyperactivity Disorder Market, By Drug Type

8.1. Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2023-2032

8.1.1 Stimulants

8.1.1.1. Market Revenue and Forecast (2019-2032)

8.1.2. Non-stimulants

8.1.2.1. Market Revenue and Forecast (2019-2032)

Chapter 9. Global Attention Deficit Hyperactivity Disorder Market, By Demographics

9.1. Attention Deficit Hyperactivity Disorder Market, by Demographics, 2023-2032

9.1.1. Children (2 to 17 years of age)

9.1.1.1. Market Revenue and Forecast (2019-2032)

9.1.2. Adults

9.1.2.1. Market Revenue and Forecast (2019-2032)

Chapter 10. Global Attention Deficit Hyperactivity Disorder Market, By Distribution Channel 

10.1. Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2023-2032

10.1.1. Retail Pharmacy

10.1.1.1. Market Revenue and Forecast (2019-2032)

10.1.2. Hospital Pharmacy

10.1.2.1. Market Revenue and Forecast (2019-2032)

Chapter 11. Global Attention Deficit Hyperactivity Disorder Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.1.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.1.4.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.1.5.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.2.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.2.4.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.2.5.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.2.6.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.2.7.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.3.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.3.4.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.3.5.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.3.6.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.3.7.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.4.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.4.4.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.4.5.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.4.6.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.4.7.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.5.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.5.4.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)

11.5.5.2. Market Revenue and Forecast, by Demographics (2019-2032)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)

Chapter 12. Company Profiles

12.1. Novartis AG

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Eli Lilly and Company

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Johnson & Johnson Services, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Lupin

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Takeda Pharmaceutical Company Limited

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Mallinckrodt plc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Pfizer, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Purdue Pharma L.P.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. NEOS Therapeutics Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Supernus Pharmaceuticals Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Frequently Asked Questions

The global attention deficit hyperactivity disorder market size was reached at USD 13.27 billion in 2022 and it is projected to hit around USD 20.06 billion by 2032.

The global attention deficit hyperactivity disorder market is growing at a compound annual growth rate (CAGR) of 4.22% from 2023 to 2032.

The North America region has accounted for the largest attention deficit hyperactivity disorder market share in 2022.

Report Details

  • Report Code:37275
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:January 2023
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers